Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global Biliary Tract Cancer Market Spotlight 2017: Eli Lily has Carried out the Most Phase II Trials in Biliary Tract Neoplasms Space, Followed by Sanofi and AstraZeneca

Research and Markets
Posted on: 15 Feb 18
Global Biliary Tract Cancer Market Spotlight 2017: Eli Lily has Carried out the Most Phase II Trials in Biliary Tract Neoplasms Space, Followed by Sanofi and AstraZeneca

PR Newswire

DUBLIN, Feb. 15, 2018

DUBLIN, Feb. 15, 2018 /PRNewswire/ --

The "Market Spotlight: Biliary Tract Cancer" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Biliary Tract Cancer market, comprising key pipeline drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.

Key Takeaways

  • The author estimates that in 2016, there were approximately 716,000 incident cases of biliary tract cancer worldwide, and forecasts that number to increase to 784,000 incident cases by 2025.
  • The majority of industry-sponsored drugs in active clinical development for biliary tract cancer are in Phase II. Therapies in mid-to-late-stage development for biliary tract cancer focus on a wide variety of targets, with the majority being administered via the oral route.
  • High-impact upcoming events include topline Phase III trial results for derazantinib. There were only three licensing and asset acquisition activities involving gallbladder and biliary tract cancer drugs during 2012-17. The exclusive acquisition agreement signed in 2017 between Mundipharma and CellAct for $250m for the acquisition of CAP7-1 was the only deal with disclosed deal value during the period.
  • The clinical trials distribution across Phase I-IV indicates that the majority of trials for biliary tract neoplasms been in the early and mid-phases of development, with 94% of trials in Phase I-II, and only 6% in Phase III.
  • The US has a substantial lead in the number of biliary tract neoplasms clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.
  • Clinical trial activity in the biliary tract neoplasms space is dominated by completed trials. AstraZeneca, Eli Lilly and Sanofi have the highest number of completed clinical trials for biliary tract neoplasms, with three completed trials each.
  • Eli Lily has carried out the most Phase II trials in biliary tract neoplasms space, followed by Sanofi and AstraZeneca

Key Topics Covered:

KEY TAKEAWAYS

DISEASE BACKGROUND
Biliary Tract Cancer Subtypes

TREATMENT
Surgery
Radiation Therapy
Chemotherapy
Palliative Therapy

EPIDEMIOLOGY

PIPELINE DRUGS

KEY UPCOMING EVENTS

LICENSING AND ASSET ACQUISITION DEALS
Mundipharma Acquires 'Smart' Chemo Drug From CellAct

PARENT PATENTS

CLINICAL TRIAL LANDSCAPE
Recent events

BIBLIOGRAPHY

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/research/7785gt/global_biliary?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-biliary-tract-cancer-market-spotlight-2017-eli-lily-has-carried-out-the-most-phase-ii-trials-in-biliary-tract-neoplasms-space-followed-by-sanofi-and-astrazeneca-300599420.html

SOURCE Research and Markets

PR Newswire
www.prnewswire.com

Last updated on: 15/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.